[
    [
        {
            "time": "",
            "original_text": "医药周报：坚守具备估值安全垫、业绩增长确定性高的二线龙头",
            "features": {
                "keywords": [
                    "医药",
                    "估值安全垫",
                    "业绩增长",
                    "二线龙头"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药周报：坚守具备估值安全垫、业绩增长确定性高的二线龙头",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "东吴证券 - 医药生物行业追踪周报：医药板块估值有多贵？哪些估值贵【行业研究】",
            "features": {
                "keywords": [
                    "东吴证券",
                    "医药生物",
                    "估值",
                    "行业研究"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "东吴证券 - 医药生物行业追踪周报：医药板块估值有多贵？哪些估值贵【行业研究】",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-02",
            "original_text": "【国元医药|行业追踪】血液制品行业追踪：2021年2月批签发追踪",
            "features": {
                "keywords": [
                    "国元医药",
                    "血液制品",
                    "批签发",
                    "2021年2月"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "血液制品"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【国元医药|行业追踪】血液制品行业追踪：2021年2月批签发追踪",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 4,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 4
            }
        }
    ]
]